



The [U.S. Department of Justice, Office of Justice Programs' Bureau of Justice Assistance](#) is pleased to announce that it is seeking applications for funding under the Harold Rogers Prescription Drug Monitoring Program. This program furthers the Department's mission by breaking the cycle of drug abuse and violence by reducing demand and enforcing laws aimed at reducing the supply of illegal drugs.

Developing and Enhancing Prescription Drug Monitoring Programs FY 2008 Competitive Grant Announcement

Eligibility

Implementation and Enhancement Grants: Applicants are limited to state governments with legislation or regulations, either pending or in place, that (1) require the submission of dispensing data to a centralized database and (2) authorize or designate a state agency to implement and administer the program. States with pending legislation or regulations may apply for an implementation grant, but will not be awarded a grant unless the legislation or regulations are in place at the time that funding decisions are made. State governments that want to improve an existing prescription drug monitoring program may apply for an enhancement award.

Planning Grants: Applicants are limited to state governments without enabling statutes or regulations.

(See "Eligibility," page 1)

Deadline

All applications are due by 8:00 p.m. e.t. on February 14, 2008.

(See "Deadline: Applications," page 1)

Contact Information

For assistance with the requirements of this solicitation, contact: Ruby Qazilbash, BJA Senior Policy Advisor, at (202) 305-6982 or Ruby.Qazilbash@usdoj.gov.

This application must be submitted through Grants.gov. For technical assistance with submitting the application, call the Grants.gov Customer Support Hotline at 1-800-518-4726.

Grants.Gov announcement number: BJA-2008-1719

Release date: October 29, 2007

CONTENTS

Overview of the Prescription Drug Monitoring Program	1
Deadline: Registration	1
Deadline: Applications	1
Eligibility	1
Prescription Drug Monitoring Program-Specific Information	2
Performance Measures	3
How To Apply	6
What An Application Must Include:	7
Standard Form 424	
Program Narrative	
Budget and Budget Narrative	
Other Attachments	
Selection Criteria	8
Review Process	9
Additional Requirements	9

Developing and Enhancing Prescription Drug Monitoring Programs

CDFA #16.580

Overview of the Prescription Drug Monitoring Program

The primary purpose of the Prescription Drug Monitoring Program (PDMP) is to enhance the capacity of regulatory and law enforcement agencies to collect and analyze controlled substance prescription data through a centralized database administered by an authorized state agency. The program was created by the FY 2002 U.S. Department of Justice Appropriations Act (Public Law 107-77) and has received funding under each year's Appropriations Act.

Deadline: Registration

Registering with Grants.gov is a one-time process; however, if you are a first-time registrant, it could take up to several weeks to have your registration validated and confirmed and to receive your user password. It is highly recommended you start the registration process as early as possible to prevent delays in submitting your application package to our agency by the deadline specified. There are three steps that you must complete before you are able to register: 1) register with Central Contractor Registry (CCR), 2) register yourself as an Authorized Organization Representative (AOR), and 3) be authorized as an AOR in your organization. For more information, go to www.grants.gov. **Note: Your CCR registration must be renewed once a year. Failure to renew your CCR registration will prohibit submission of a grant application through Grants.gov.**

Deadline: Applications

The due date for applying for funding under this announcement is 8:00 p.m. e.t. on February 14, 2008.

Eligibility

States ("states" includes the 50 states, the District of Columbia, Commonwealth of Puerto Rico, Northern Mariana Islands, U.S. Virgin Islands, Guam, and American Samoa) are eligible for implementation and enhancement grants if they have in place an enabling statute or regulation requiring the submission of controlled substance prescription data to an authorized state agency. The legislation or regulations should include:

- The required submission of data for prescriptions in Schedules II, III, IV, and V.
- The submission of data elements consistent with standards established by the American Society for Automation in Pharmacy.
- Access to collected data by federal, state, and local law enforcement personnel statutorily authorized to access prescription data by traditional, manual methods.

For information on model PDMP legislation, visit www.natlalliance.org/pdfs/v3a%20model%20prescription%20monitoring%20act.pdf or www.nascsa.org/Folder1/modelact.htm.

State governments are eligible for planning grant funds if they do not have enabling statutes or regulations in place.

Prescription Drug Monitoring Program-Specific Information

All awards are subject to the availability of appropriated funds and any modifications or additional requirements that may be imposed by law.

The Prescription Drug Monitoring Program assists states as they plan, implement, or enhance a PDMP. PDMPs:

- Build a data collection and analysis system at the state level.
- Enhance existing programs' abilities to analyze and use collected data.
- Facilitate national evaluation efforts.
- Encourage the exchange of information and collected prescription data among states.
- Assess the efficiency and effectiveness of programs.
- Enhance collaborations with law enforcement, prosecutors, treatment professionals, the medical community, and pharmacies.

The Office of Justice Programs' Bureau of Justice Assistance (BJA) administers this program with the U.S. Drug Enforcement Administration's (DEA) Office of Diversion Control and the Office of National Drug Control Policy (ONDCP).

Award Categories

States may submit a PDMP application in one of three categories:

CATEGORY I: PLANNING. Grant maximum: \$50,000. Project period: 15 months.

States without a PDMP may apply for a planning grant, and need not have legislation or regulations pending or in place. Funds may be used to assist states in planning for a data collection and analysis system. Activities could include creating a planning advisory committee and ensuring key stakeholders in the state are involved in the planning process.

CATEGORY II: IMPLEMENTATION. Grant maximum: \$400,000. Project period: 24 months.

States that have in place legislation or regulations that require the submission of dispensing data to a centralized database and authorize and/or designate a state agency to provide program oversight and implementation may apply for an implementation grant. States developing a voluntary pilot program also may apply for an implementation grant. Funds may be used to plan, establish, and build a data collection and analysis system; develop an infrastructure to support programmatic activities; facilitate the exchange of information and collected prescription data among states; facilitate the establishment of collaborations; develop a training program for system users; produce and disseminate educational materials; and assess the efficiency and effectiveness of the program.

Category III: ENHANCEMENT. Grant maximum: \$400,000. Project period: 24 months.

States seeking to improve existing PDMPs are eligible to apply for an enhancement grant. Funds may be used to enhance a data collection and analysis system; develop infrastructure to support programmatic activities; enhance an existing training program; support collaborations with law enforcement and prosecutors; support collaborations with treatment providers and drug courts; facilitate information sharing among states; expand monitoring to Schedules III, IV, and

V; and assess the efficiency and effectiveness of the program. Funds should be used to enhance the functioning of an existing program. Applications should not request support for day-to-day program operations.

Limitation on use of award funds for employee compensation; waiver: No portion of any award of more than \$250,000 made under this solicitation may be used to pay any portion of the total cash compensation (salary plus bonuses) of any employee of the award recipient whose total cash compensation exceeds 110 percent of the maximum annual salary payable to a member of the Federal government’s Senior Executive Service (SES) at an agency with a Certified SES Performance Appraisal System for that year. (The salary table for SES employees is available at www.opm.gov.)

This prohibition may be waived at the discretion of the Assistant Attorney General for the Office of Justice Programs. An applicant that wishes to request a waiver should include a detailed justification in the budget narrative for the application.

Performance Measures

To assist in fulfilling the Department’s responsibilities under the Government Performance and Results Act (GPRA), P.L. 103-62, applicants who receive funding under this solicitation must provide data that measures the results of their work. Performance measures for this solicitation are as follows:

Program Goals	Performance Measures	Data Grantee Provides
<p>1) Reduce the rate of “inappropriate use of prescription drugs.”</p>	<ul style="list-style-type: none"> The number of Licensed PRESCRIBERS, DISPENSERS, and INDIVIDUALS AUTHORIZED TO CONDUCT INVESTIGATIONS that were trained in the use of the state’s PDM system. 	<ul style="list-style-type: none"> For this reporting period, how many licensed PRESCRIBERS were trained formally (in a classroom setting) in the use of the PDM system? For this reporting period, how many licensed PRESCRIBERS were trained informally (e.g., via the Internet, mass mailings, and so on) in the use of the PDM system? For this reporting period, how many licensed PRESCRIBERS are there in your state? As of the last day of this reporting period, how many licensed PRESCRIBERS would you say have been trained informally in the use of the system? For this reporting period, how many licensed DISPENSERS were trained formally (in a classroom setting) in the use of the PDM system? For this reporting period, how many licensed DISPENSERS were trained informally (e.g., via the Internet, mass mailings, and so on) in the use of the PDM system?

		<ul style="list-style-type: none"> • For this reporting period, how many licensed DISPENSERS are there in your state? • As of the last day of this reporting period, how many licensed DISPENSERS would you say have been trained informally in the use of the system? • For this reporting period, how many INDIVIDUALS AUTHORIZED TO CONDUCT INVESTIGATIONS were trained formally (in a classroom setting) in the use of the PDM system? • For this reporting period, how many INDIVIDUALS AUTHORIZED TO CONDUCT INVESTIGATIONS were trained informally (e.g., via the Internet, mass mailings, and so on) in the use of the PDM system? • For this reporting period, how many INDIVIDUALS AUTHORIZED TO CONDUCT INVESTIGATIONS are there in your state? • As of the last day of this reporting period, how many INDIVIDUALS AUTHORIZED TO CONDUCT INVESTIGATIONS would you say have been trained informally in the use of the system?
	<ul style="list-style-type: none"> • The number of coroner reports that indicate controlled prescription drug use as the primary or contributing cause of death. 	<ul style="list-style-type: none"> • For this reporting period, how many coroner reports indicated that controlled prescription drug use was the primary or contributing cause of death?
<p>2) Reduce the quantity of pharmaceutical controlled substances obtained by individuals attempting to engage in fraud and deceit (i.e., “doctor shopping”).</p>	<ul style="list-style-type: none"> • Increase in the number of reports generated. • The number of individuals that filled prescriptions from multiple pharmacies. 	<ul style="list-style-type: none"> • For PRESCRIBERS: <ul style="list-style-type: none"> ○ For this reporting period, how many solicited reports were produced? ○ For this reporting period, how many unsolicited reports were produced? • For DISPENSERS: <ul style="list-style-type: none"> ○ For this reporting period, how many solicited reports were produced? ○ For this reporting period, how many unsolicited reports were produced? • For INDIVIDUALS AUTHORIZED TO CONDUCT INVESTIGATIONS: <ul style="list-style-type: none"> ○ For this reporting period, how many solicited reports were produced? ○ For this reporting period, how many unsolicited reports were produced? • For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II drugs?

		<ul style="list-style-type: none"> • For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II drugs from 5 or more PRESCRIBERS at 5 or more pharmacies? • For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II drugs from 10 or more PRESCRIBERS at 10 or more pharmacies? • For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II drugs from 15 or more PRESCRIBERS at 15 or more pharmacies?
		<ul style="list-style-type: none"> • For this reporting period, how many non-liquid doses of the following were associated with INDIVIDUALS that filled prescriptions for Schedule II drugs: <ul style="list-style-type: none"> ○ Pain relievers. ○ Tranquilizers. ○ Stimulants. ○ Sedatives. • For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III drugs? • For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III drugs from 5 or more PRESCRIBERS at 5 or more pharmacies? • For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III drugs from 10 or more PRESCRIBERS at 10 or more pharmacies? • For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III drugs from 15 or more PRESCRIBERS at 15 or more pharmacies? • For this reporting period, how many non-liquid doses of the following were associated with INDIVIDUALS that filled prescriptions for Schedule II, III drugs: <ul style="list-style-type: none"> ○ Pain relievers. ○ Tranquilizers. ○ Stimulants. ○ Sedatives. • For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III, IV drugs?

		<ul style="list-style-type: none"> • For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III, IV drugs from 5 or more PRESCRIBERS at 5 or more pharmacies? • For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III, IV drugs from 10 or more PRESCRIBERS at 10 or more pharmacies? • For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III, IV drugs from 15 or more PRESCRIBERS at 15 or more pharmacies? • For this reporting period, how many non-liquid doses of the following were associated with INDIVIDUALS that filled prescriptions for Schedule II, III, IV drugs: <ul style="list-style-type: none"> ○ Pain relievers. ○ Tranquilizers. ○ Stimulants. ○ Sedatives.
3) Increase coordination among PDMP partners (e.g., regulatory, health, law enforcement agencies.)	<ul style="list-style-type: none"> • The number of licensed PRESCRIBERS and DISTRIBUTORS trained formally in coordinating and sharing data. 	<ul style="list-style-type: none"> • How many licensed PRESCRIBERS and DISTRIBUTORS were trained formally in coordination and data sharing? • How many PDMP partners were trained in coordination of data sharing?
4) Involve stakeholders in the planning process.	<ul style="list-style-type: none"> • For planning grantees: Percentage of stakeholder involvement. 	<ul style="list-style-type: none"> • Number of stakeholders engaged in the project through memorandums of understanding, meeting attendance, etc. • Total number of stakeholders necessary to affect policy change.

How To Apply

DOJ is participating in the e-Government initiative, one of 25 initiatives included in the President’s Management Agenda. Part of this initiative—Grants.gov—is a “one-stop storefront” that provides a unified process for all customers of federal grants to find funding opportunities and apply for funding.

Grants.gov Instructions: Complete instructions can be found at www.grants.gov. If you experience difficulties at any point during this process, please call the Grants.gov Customer Support Hotline at **1-800-518-4726**.

Note: Grants.gov does not support the Microsoft Vista Operating system. The PureEdge software used by Grants.gov for forms is not compatible with Vista. Also, Grants.gov cannot yet

process Microsoft Word 2007 documents saved in the new default format with the extension ".DOCX." Please ensure the document is saved using "Word 97-2003 Document (*.doc)" format.

Please also note: OJP's GMS does not accept executable file types as application attachments. These disallowed file types include, but are not limited to, the following extensions: ".com," ".bat," ".exe," ".vbs," ".cfg," ".dat," ".db," ".dbf," ".dll," ".ini," ".log," ".ora," ".sys," and ".zip."

CFDA Number: The Catalog of Federal Domestic Assistance (CFDA) number for this solicitation is 16.580, titled "Edward Byrne Memorial State and Local Law Enforcement Assistance Discretionary Grants Program," and the funding opportunity number is BJA-2008-1719.

A DUNS number is required: The Office of Management and Budget requires that all businesses and nonprofit applicants for federal funds include a DUNS (Data Universal Numeric System) number in their application for a new award or renewal of an award. Applications without a DUNS number are incomplete. A DUNS number is a unique nine-digit sequence recognized as the universal standard for identifying and keeping track of entities receiving federal funds. The identifier is used for tracking purposes and to validate address and point of contact information. The DUNS number will be used throughout the grant life cycle. Obtaining a DUNS number is a free, simple, one-time activity. Obtain one by calling 1-866-705-5711 or by applying online at www.dunandbradstreet.com. Individuals are exempt from this requirement.

What an Application Must Include

Standard Form 424

Program Narrative (Attachment 1)

The program narrative must respond to the solicitation and the Selection Criteria (1-3, 5) in the order given. The program narrative must be double-spaced, using a standard 12-point font (Times New Roman is preferred) with 1-inch margins, and must not exceed 20 pages. Please number pages "1 of 20," "2 of 20," etc. **At the beginning of the Program Narrative, indicate which category (Category I: Planning, Category II: Implementation, or Category III: Enhancement) you are applying for.** Submissions that do not adhere to the format may be deemed ineligible.

Budget and Budget Narrative (Attachment 2)

Applicants must provide a budget that is complete and allowable. Applicants must submit a budget worksheet and budget narrative in one file. A fillable budget detail worksheet form is available on OJP's web site at www.ojp.usdoj.gov/Forms/budget_fillable.pdf. Include funding to support attendance at two or three national or regional planning and coordination meetings.

Project Timeline and Position Descriptions/Résumés (Attachment 3)

Attach a *Project Timeline* with each project goal, related objective, activity, expected completion date, and responsible person or organization; and *Position Descriptions* for key positions and résumés for current staff. Do not include materials not requested in this attachment; additional material will not be reviewed.

Selection Criteria

1. Statement of the Problem (10 points)

Describe the impact that the abuse and diversion of controlled substances is having on your state. Provide data to support your discussion. Explain the current system in your state for collecting information on the abuse of controlled substances. Analyze the weaknesses or omissions of the current methods of data collection and analysis.

2. Program Design and Implementation (50 points)

Strategy Overview (15 points): A clear connection should be shown between the proposed strategy and the problem. Summarize the state's overall strategy to reduce the abuse and diversion of pharmaceutical controlled substances. Describe current law enforcement activities and/or government and industry partnerships addressing this problem and describe how the state's PDMP fits into this strategy. For Implementation and Enhancement applications, identify the statute that provides for a prescription drug monitoring database, the state agency that has been designated to carry out the mandates of this legislation, and how that agency is positioned to implement the activities proposed by this grant.

Implementation (20 points): Describe what the state proposes to do and how the state will do it. Include a project timeline (in Attachment 3) that describes each project goal, related objective, activity, expected completion date, and responsible person or organization. Briefly explain how each task will support and/or enhance the development of the PDMP.

Collaboration (15 points): Identify who the state agency will collaborate with (e.g., state, regulatory, and law enforcement officials; health care professionals; consumers), their responsibilities, and how the state will involve them in planning and/or enhancing the PDMP and providing outreach to the community. Describe the strategy to collaborate with other public and private agencies and organizations. Include any previous collaboration that occurred in the PDMP.

3. Capabilities/Competencies (10 points)

Describe the management structure and staffing, specifically identifying the key person responsible for carrying out program activities. Demonstrate the capability to implement the project successfully. Provide job descriptions outlining the roles and responsibilities of key positions and résumés for current staff (in Attachment 3).

4. Budget (10 points)

Provide a proposed budget that is complete and allowable (see Attachment 2). Include funding to support attendance at two or three national or regional planning and coordination meetings.

5. Impact/Outcomes, Evaluation, and Sustainment (20 points)

Explain how the state will know if the program works in order to assess the impact of its efforts. Describe the data the state already has and the data it will collect to show a reduction in diversion and abuse. Explain what will be measured, who is responsible for performance measures, and how the information will be used. Outline a strategy for sustaining the project when the federal grant ends.

Review Process

All applications will be peer reviewed. The BJA Director will then make award recommendations to the Office of Justice Programs' Assistant Attorney General, who will make final determinations.

Additional Requirements

- Civil Rights compliance.
- Confidentiality and Human Subjects Protections regulations.
- Anti-Lobbying Act.
- Financial and Government Audit requirements.
- National Environmental Policy Act (NEPA) compliance.
- DOJ Information Technology Standards.
- Single Point of Contact Review.
- Non-Supplanting of State or Local Funds.
- Criminal Penalty for False Statements.
- Compliance with Office of the Comptroller *Financial Guide*.
- Suspension or Termination of Funding.

We strongly encourage you to review the information pertaining to these additional requirements prior to submitting your application. Additional information for each can be found at www.ojp.usdoj.gov/funding/otherrequirements.htm.